Vendor qualification in pain management settings
Pain management and physical medicine practices commonly handle biologics vendor review the same way they handle other ancillary product lines: an office manager or administrator collects vendor documentation, and a physician or medical director signs off before a first order is placed.
Because Precision Biologics is a distributor rather than the manufacturer, practices should expect to receive processing and donor-eligibility documentation describing the supplier's HCT/P framework rather than clinical study data, and can request that documentation before committing to a purchase.
Columbus
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
27- Pain Medicine
- 17
- Physical Medicine & Rehabilitation
- 10
Receiving and storing shipments in the Southeast
Shipments of cryopreserved Wharton's jelly products travel overnight on dry ice in validated containers and are stored at -80 degrees Celsius once they arrive, which a Columbus-area practice should plan for by having freezer capacity ready in advance.
Lyophilized exosome formats are described by the supplier as shelf-stable, which can simplify receiving for practices that prefer not to manage cryogenic storage for every product line.
NPI verification and ongoing account access
An NPI number is required to open and verify an account, consistent with sales being limited to licensed physicians and clinics operating under physician supervision rather than to the public.
Verified accounts can request physician-level conversations about documentation, a certificate of analysis and lot release record per shipment, and the full ingredient disclosure available for exosome products.
Where regulatory confirmation belongs
FDA has stated there are no FDA-approved exosome products, and these are generally regulated as biologic drugs; purchase and clinical use decisions for any exosome product rest with the treating physician and their own regulatory counsel, not with the supplier.
For Wharton's jelly products, whether a specific intended use satisfies the minimal-manipulation and homologous-use criteria under federal regulation is a determination practices should confirm with the Georgia Composite Medical Board's requirements and their own legal counsel.
Keeping that confirmation on file alongside the lot's certificate of analysis gives a practice a complete record if its vendor qualification process is ever reviewed internally.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does the provider count include practices just outside Columbus?+
No. The 27-provider figure reflects NPPES records with a primary practice location listed as Columbus and excludes nearby communities in the wider metro area.
Are exosome products FDA approved?+
No. FDA has stated there are no FDA-approved exosome products, and they are generally regulated as biologic drugs; any purchase or clinical use decision should involve the practice's own regulatory counsel.
What do we need to request before our first order?+
A certificate of analysis, donor eligibility summary, and lot release record for the specific lot being purchased, plus full ingredient disclosure for exosome products, all available to verified accounts on request.